Dentium 2026 Q1: Consolidated Revenue of 321 Million RMB, China Market Revenue Share Rises to 45%

Source: Dentium 2026 Q1 Report

China Revenue Share Rises to 45% / Q1 Cancels 2,444,939 Shares / R&D Expense Ratio Increases to 3.7%

DentalGoodNews｜South Korean dental implant company Dentium (Dentium Co., Ltd., KOSPI: 145720) released its Q1 2026 report on May 15, 2026. The report shows consolidated operating revenue of approximately KRW 71.383 billion (about RMB 321 million) for the quarter, down about 7.1% from KRW 76.834 billion (about RMB 346 million) in Q1 2025. Operating profit was KRW 8.341 billion (about RMB 37.535 million), slightly down from KRW 9.584 billion (about RMB 43.128 million) in the same period of 2025. Net profit attributable to parent company shareholders was KRW 17.196 billion (about RMB 77.382 million), and consolidated net profit was KRW 17.055 billion (about RMB 76.7475 million), up approximately 34.5% year-on-year from KRW 12.682 billion (about RMB 57.069 million) in Q1 2025.

Source: Dentium 2026 Q1 Report

In terms of regional revenue structure, Q1 2026 China market revenue was KRW 32.119 billion (about RMB 145 million), accounting for 45.0% of total group revenue, higher than the 38.3% share for the full year 2025 (when full-year China revenue was approximately KRW 132.589 billion, about RMB 597 million). South Korea domestic market revenue was approximately KRW 15.241 billion (about RMB 68.5845 million), accounting for 21.4%; other Asian regions contributed approximately KRW 14.997 billion (about RMB 67.4865 million), or 21.0%; Europe contributed approximately KRW 7.583 billion (about RMB 34.1235 million), or 10.6%; and other regions contributed approximately KRW 1.442 billion (about RMB 6.489 million), or 2.0%.

Source: Dentium 2026 Q1 Report

By product structure, Q1 2026 revenue from dental implant-related products (Implantium series, etc.) was approximately KRW 54.100 billion (about RMB 243 million), accounting for 75.8%; digital equipment (such as CBCT Rainbow CT) revenue was approximately KRW 8.476 billion (about RMB 38.142 million), accounting for 11.9%; biological regenerative materials (synthetic bone OSTEON, etc.) were approximately KRW 4.073 billion (about RMB 18.3285 million), accounting for 5.7%; service revenue was approximately KRW 2.605 billion (about RMB 11.7225 million), accounting for 3.6%; and other categories totaled approximately KRW 2.129 billion (about RMB 9.5805 million), accounting for about 3.0%. The company emphasized that its internalization rate (self-produced products accounting for 88%) is higher than that of major competitors, and this ratio has remained stable over the past three years.

Source: Dentium 2026 Q1 Report

In terms of capital returns, on February 9, 2026, the company canceled 814,980 common shares through profit transfer, costing approximately KRW 814 million (about RMB 3.663 million). On March 11, it canceled another 1,629,959 shares, costing approximately KRW 7.938 billion (about RMB 35.721 million). A total of 2,444,939 shares were canceled, reducing outstanding common shares from 11,198,830 to 8,623,891, a decrease of 21.8%. Additionally, the company launched a new round of trust buybacks from April 1, 2026, to March 31, 2027, with a planned maximum repurchase scale of KRW 60 billion (about RMB 270 million). In the first month, approximately KRW 550 million (about RMB 2.475 million) was purchased (execution progress 9.2%). The potential total scale of the two rounds of capital operations exceeds KRW 17.86 billion (about RMB 80.37 million).

Source: Dentium 2026 Q1 Report

On the production side, capacity utilization rates at the three factories in Q1 2026 were all lower than the full-year 2025 levels. The Gwangju factory in South Korea had an actual utilization rate of 40.0% in Q1 2026, continuing to decline from 54.1% in full-year 2025 and 75.4% in 2024. The Da Nang factory in Vietnam had a utilization rate of 58.2%, down from 86.0% in 2025. The Shanghai factory had a utilization rate of 73.2%, down from 92.8% in 2025.

Source: Dentium 2026 Q1 Report

Regarding R&D investment, R&D expenses in Q1 2026 were approximately KRW 1.879 billion (about RMB 84.555 million), accounting for about 3.7% of quarterly revenue on a separate financial statement basis, higher than the full-year 2025 ratio of 3.1% and the full-year 2024 ratio of 2.6%. On a consolidated basis, the ratio was about 2.63%. Major ongoing R&D projects include the Pin Guide Kit bone positioning guide system, narrow-diameter implant Bone Level FX30, orthodontic product line (Orthodontic Screw/Bracket), GBR system upgrade for bone augmentation, and commercialization of solid oxide fuel cells (SOFC).